Latex Agglutination Turbidimetric Immunoassay Versus Enzyme-Linked Immunosorbent Assay for Helicobacter pylori: An Observational Study.

Yoshitaka Tokai (✉ yoshitaka.tokai@jfcr.or.jp)
The Cancer Institute Hospital

Junko Fujisaki
The Cancer Institute Hospital

Naoki Ishizuka
The Cancer Institute Hospital

Hiroki Osumi
The Cancer Institute Hospital

Ken Namikawa
The Cancer Institute Hospital

Shoichi Yoshimizu
The Cancer Institute Hospital

Yusuke Horiuchi
The Cancer Institute Hospital

Akiyoshi Ishiyama
The Cancer Institute Hospital

Toshiyuki Yoshio
The Cancer Institute Hospital

Toshiaki Hirasawa
The Cancer Institute Hospital

Kazumasa Miki
The Cancer Institute Hospital

Tomohiro tsuchida
The Cancer Institute Hospital

Research Article

Keywords: Helicobacter pylori, Enzyme-Linked Immunosorbent Assay, Latex Agglutination Tests

DOI: https://doi.org/10.21203/rs.3.rs-120423/v1
Abstract

**Background:** *Helicobacter pylori* antibody levels in the blood are currently measured using an enzyme-linked immunosorbent assay (ELISA). In April 2016, FUJIFILM Wako Pure Chemical Corporation launched the “L-type Wako *Helicobacter pylori* antibody J” test, which is based on the latex agglutination turbidimetric immunoassay. In this study, we investigated the usefulness of the Wako test.

**Methods:** We measured *H. pylori* antibody levels using both ELISA and Wako tests in 180 patients who underwent esophagogastroduodenoscopy at our hospital between September 2017 and February 2019. Ninety patients had *H. pylori* infections. We calculated the diagnostic accuracy, sensitivity, and specificity of each test and the concordance rate between the two tests. If the lower limits of 90% confidence intervals (CI) for each diagnostic validity exceeded the 85% threshold, the usefulness of the diagnostic test was confirmed.

**Results:** Diagnostic accuracy, sensitivity, and specificity were 94.4% (90% CI; 90.8–97.0%), 94.4% (90% CI; 88.7–97.8%), and 94.4% (90% CI; 88.7–97.8%), respectively, using the Wako test, and 94.4% (90% CI; 90.8–97.0%), 88.9% (90% CI; 81.9–93.8%), and 100% (90% CI; 96.0–100%), respectively, using ELISA. The concordance rate between the two tests was high (κ = 0.8444).

**Conclusions:** We confirmed the usefulness of the Wako test, especially when screening for *H. pylori* infection, due to its high sensitivity.

**Trial registration:** We retrospectively registered the data of this study.

Background

*Helicobacter pylori,* a gram-negative bacillus, was discovered in 1983 by Warren and Marshall and is known to persistently infect the human gastric mucosa and induce histological gastritis accompanied by neutrophilic infiltration [1]. It has been demonstrated that *H. pylori* infection is associated with the development of gastric ulcer/duodenal ulcers and gastric cancer [2]. In 1994, the International Agency for Research on Cancer, an external organisation of the World Health Organisation, reported that *H. pylori* is a cause of gastric cancer [3].

People in Japan were notified that eradication therapy for *H. pylori*-infected gastritis would be covered by health insurance starting February 2013; thus, the diagnosis of *H. pylori* infection became more prevalent.

Diagnostic methods for *H. pylori* infection with endoscopy include the culture test, microscopic test, and rapid urease test. The tests without endoscopy include the urea breath test (UBT), blood *H. pylori* antibody test, and faeces *H. pylori* antigen test [4, 5]. According to the Japanese Society for *Helicobacter* Research guidelines [6], UBT is the most accurate among the tests, and its sensitivity and specificity are 98% [7].

The blood *H. pylori* antibody test is convenient and widely used to diagnose *H. pylori* infection in current clinical practice. The prevailing methods for this antibody test are the enzyme-linked immunosorbent assay
(ELISA, Eiken Chemical, Tokyo, Japan) and the chemiluminescent method, both of which have limitations: analysis is time-consuming and requires special measuring devices.

In April 2016, FUJIFILM Wako Pure Chemical Corporation launched the “L-type Wako \textit{H. pylori} antibody J” (L-HP•J) test (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), which is based on the latex agglutination turbidimetric immunoassay.

Since this kit can be used with a general-purpose automatic analyser, it is less complicated than ELISA. Many samples can be analysed simultaneously, rapidly, and more economically using this kit. Another advantage of this kit is that the presence of \textit{H. pylori} infection can be diagnosed, and drugs can be prescribed to eradicate \textit{H. pylori} on the same day as the blood test. Consequently, this kit might contribute to reduced medical costs; however, its accuracy has not been confirmed. In this study, we evaluated the diagnostic validity of the L-HP•J test, which has not yet been demonstrated, by calculating and comparing its diagnostic accuracy, sensitivity, specificity, and concordance rate with those of the standard ELISA method.

**Methods**

**Patients**

This observational study was conducted in clinical settings and included consecutive patients who underwent gastrointestinal endoscopy between September 2017 and February 2019. The following patients were excluded: those who had received eradication therapy for \textit{H. pylori} or had undergone gastrectomy; those who had taken proton pump inhibitors within 2 weeks before undergoing the UBT; those who had taken antibiotics within 4 weeks before the endoscopy; those who had undergone head and neck surgery and were unable to undergo the UBT; those in whom advanced gastric cancer was detected endoscopically, and those who were suspected of having type A gastritis endoscopically (cases with severe atrophic gastritis of the corpus and mild or no atrophic gastritis of the antrum). Our medical staff interviewed the patients to determine whether they had received eradication therapy for \textit{H. pylori} or had undergone gastrectomy in the past. Major reasons for undergoing gastrointestinal endoscopy included screening, testing positive for \textit{H. pylori} antibodies, having abdominal symptoms such as upper abdominal pain, and workup for early gastric cancer. Ultimately, 180 patients were enrolled in the study.

**Serum \textit{H. pylori} kits and assay procedure**

We measured \textit{H. pylori} antibodies in-house, in specimens from subjects who provided consent, using (1) the L-HP•J test and (2) the E-plate “Eiken” \textit{H. pylori} antibody test (ELISA). Blood sampling was performed on the same day as endoscopy. Cut-off values used for these antibody tests were as follows: (1) L-HP•J test, 4 U/mL or more was considered positive for \textit{H. pylori}, and (2) ELISA, 10 U/mL or more was considered positive for \textit{H. pylori}. Measurement using each kit was performed in-house. In this study, we used a full automatic plate chemiluminescence analyser (Hitachi Chemical Diagnostics Systems Co., Ltd., Tokyo, Japan) for ELISA, and Hitachi Labospect 008 automatic biochemistry analyser (Hitachi High-Technologies, Tokyo, Japan) for the L-HP•J test. The ELISA consists of a combination of manual (by hand)
and automated (by auto) steps (Fig. 1). First, the specimen and buffer are manually dispensed into the wells of a 96-well microplate. This step may require a few minutes per sample, as processing speed is dependent on the technician's skill level. An automated washing step is then performed to remove any unbound antibodies. A number of additional incubation and washing steps are performed before the automated analysis of the microplate. The entire process takes approximately 87 minutes to analyse all 96 specimens. In contrast, the latex agglutination turbidimetric immunoassay does not require the incubation and washing steps that the ELISA does; hence, one specimen can be analysed in 10 minutes, and the results of 100 specimens can be obtained in 16 min. Reagents were provided by the FUJIFILM Wako Pure Chemical Corporation. Fresh plasma was used for analysis via ELISA, and cryopreserved sera (−20 °C; harvested within 4 weeks) or fresh plasma were thawed and used for analysis via the L-HP•J test.

**Endoscopic findings**

Esophagogastroduodenoscopy (EGD) was performed with the Evis Lucera Elite system (Olympus Corporation, Tokyo, Japan) and a GIF-H290Z scope (Olympus Corporation). EGD was performed by endoscopists who have 5000 cases or more of experience in EGD. The grading of gastric mucosal atrophy by endoscopic findings was based on the Kimura-Takemoto classification [8]: no atrophy (C-0); closed-type (C-1 to C-3), in which an endoscopic atrophic border is in the lesser curvature of the gastric body and does not extend beyond the cardia; and open-type (O-1 to O-3), in which an endoscopic atrophic border extends beyond the cardia and progresses into the greater curvature.

Findings that suggest active gastritis, such as spotty or diffuse redness from the gastric body to the fundus, accompanied by disappearance of the regular arrangement of collecting venules, enlarged/tortuous folds, mucosal swelling, and sticky mucus according to the Kyoto classification of gastritis [9], were considered as presence of *H. pylori* infection (Fig. 2).

**Criteria for determining *H. pylori* infection status and methods to evaluate the kits**

*H. pylori* infection was diagnosed by integrating the endoscopic findings and the UBT results as follows: Subjects who had no gastric mucosal atrophy or any findings suggestive of active gastritis on EGD as described above, and whose UBT results were negative (≥ 2.5‰ was defined as positive) (UBIT, Otsuka Pharmaceutical), were considered uninfected, while those who had findings of either gastric mucosal atrophy or active gastritis detected by EGD with a positive UBT result were considered as infected. Patients whose endoscopic findings and UBT results had a discrepancy, such as active gastritis detected endoscopically, indicating a current *H. pylori* infection, but negative UBT results, and conversely, patients who were not infected according to their endoscopic findings but whose UBT results were positive, were excluded from the study.

Subjects whose endoscopic findings and UBT results concurred in terms of the presence/absence of *H. pylori* infection were diagnosed as being positive or negative for *H. pylori*, and the sensitivity, specificity, and diagnostic accuracy of the L-HP•J test were determined. ELISA was performed in a similar manner, and the
concordance rate with the L-HP•J test was calculated. In cases misdiagnosed by the L-HP•J test, the test results correlated with the clinical findings.

**Sample size calculation**

According to a previous report from Japan, the sensitivity and specificity of the L-HP•J test for *H. pylori* positive cases were 96.4% (currently infected; 56 cases) and 97.7% (uninfected; 86 cases), respectively. Therefore, we set the expected value as 95%, and threshold value as 85% for both sensitivity and specificity. Based on the binomial test, a sample size of 85 cases was deemed to be required for both uninfected and currently infected cases using the following criteria: one-sided alpha of 5% and power of 90%. Ultimately, a total of 180 patients (90 uninfected and 90 currently infected cases) were enrolled to compensate for any dropouts.

**Statistical analyses**

All continuous variables are expressed as the median and range. For diagnostic performance, diagnostic accuracy, sensitivity, and specificity are presented as percentages with a confidence interval (CI) of 90%. To evaluate concordance between the test methods for positivity and negativity, the $\kappa$ statistic was used. McNemar’s test, which evaluates marginal homogeneity between two test methods, was used to compare the L-HP•J test and ELISA. A $P$-value $< 0.05$ was considered statistically significant. Statistical analysis was performed using Statistical Analysis System (SAS) software 9.4 (TS1M5, SAS Institute Inc., Cary, NC, USA).

**Ethics**

This study was approved by the Institutional Review Board of Cancer Institute Hospital (No. 2016 – 1208), and performed in compliance with the principles of the Declaration of Helsinki and its later amendments. While recording the data for this study, all personal identifying information was removed. Informed consent for the use of pathological specimens and imaging data for research purposes was obtained from each patient.

**Results**

**Breakdown of H. pylori infection status**

Among the 180 patients, 90 patients (50%) were uninfected and 90 patients (50%) had a *H. pylori* infection. Regarding the patient characteristics of uninfected and currently infected cases, the median age and percentage of male patients was 57 years (range; 37–76), and 65 years (range; 28–87), 45.6% and 57.8%, respectively. The uninfected group was younger in age. Among the currently infected subjects, the degree of gastric mucosal atrophy (the Kimura-Takemoto classification) was C-1 to C-3 in 51.1% (46/90) and O-1 to O-3 in 48.9% (44/90). Although the major comorbidity in the currently infected subjects was early gastric cancer, this was seen only in one patient among the uninfected subjects (Table 1).
Table 1
Characteristics of subjects with and without a current *Helicobacter pylori* infection.

|                        | Uninfected n = 90 | Currently infected n = 90 | P-value |
|------------------------|-------------------|---------------------------|---------|
| Age, median (range)    | 57 (37–76)        | 65 (28–87)                | < 0.001|
| Sex, n (%)             |                   |                           |         |
| Male                   | 41 (45.6%)        | 52 (57.8%)                | 0.14    |
| Female                 | 49 (54.4%)        | 38 (42.2%)                |         |
| Degree of atrophy, n (%)|                  |                           | < 0.001|
| No atrophy             | 90 (100%)         | 0 (0%)                    |         |
| Closed-type atrophy    | 0 (0%)            | 46 (51.1%)                |         |
| Open-type atrophy      | 0 (0%)            | 44 (48.9%)                |         |
| Titre of L-HP•J test (U/mL), median (range) | 0.75 (0-13.6)      | 32.7 (2.7-109.8)          | < 0.001|
| UBT (%), median (range) |                   |                           | < 0.001|
| Comorbidity            |                   |                           |         |
| Early gastric cancer, n (%) | 1 (1.1%)        | 28 (31.1%)                | < 0.001|
| Superficial oesophageal cancer, n (%) | 1 (1.1%)     | 0 (0%)                    |         |
| Duodenal cancer, n (%) | 0 (0%)            | 2 (2.2%)                  | 0.49    |
| Post ESD for early gastric cancer, n (%) | 0 (0%)         | 1 (1.1%)                  | 1       |
| Post ESD for superficial oesophageal cancer, n (%) | 0 (0%)         | 1 (1.1%)                  | 1       |
| Gastric ulcer scar, n (%) |                 |                           |         |

ESD, Endoscopic submucosal dissection; UBT, Urea breath test; L-HP•J, L-type Wako *Helicobacter pylori* antibody J.

### Diagnostic validity of the L-HP•J test (diagnostic accuracy, sensitivity, and specificity)

The diagnostic accuracy, sensitivity, and specificity for current *H. pylori* infection were 94.4% (90% CI; 90.8–97.0%), 94.4% (90% CI; 88.7–97.8%), and 94.4% (90% CI; 88.7–97.8%), respectively, when the L-HP•J test was used, and 94.4% (90% CI; 90.8–97.0%), 88.9% (90% CI; 81.9–93.8%), and 100% (90% CI; 96.0–100%), respectively, when ELISA was used (Table 2). Although the lower limits of 90% CI of the L-HP•J test exceeded the threshold value (85%) in terms of diagnostic accuracy, sensitivity, and specificity, the lower limits of 90% CI for sensitivity of ELISA (81.9%) were lower than the threshold value (85%).
Table 2
Diagnostic validity of the L-type Wako *Helicobacter pylori* antibody J test and the Enzyme-Linked Immunosorbent Assay.

|                      | L-HP•J test | ELISA          |
|----------------------|-------------|----------------|
| Diagnostic accuracy, %| 94.4%       | 94.4%          |
| (90% CI)             | (90.8–97.0%)| (90.8–97.0%)   |
| Sensitivity, %       | 94.4%       | 88.9%          |
| (90% CI)             | (88.7–97.8%)| (81.9–93.8%)   |
| Specificity, %       | 94.4%       | 100%           |
| (90% CI)             | (88.7–97.8%)| (96.0–100%)    |

ELISA, Enzyme-Linked Immunosorbent Assay; L-HP•J, L-type Wako *Helicobacter pylori* antibody J; 90% CI, 90% Confidence Interval.

**Comparison of concordance rates with ELISA (conventional test)**

The number of subjects who were positive for anti-*H. pylori* antibody using the ELISA and L-HP•J test were 80 and 90, respectively. The concordance rates between the L-HP•J test and ELISA were high ($\kappa = 0.8444$) (Table 3). Subsequently, using McNemar’s test, we analysed the tendency for positive or negative results for *H. pylori* between the L-HP•J test and ELISA. The results revealed that ELISA had a significant tendency to evaluate the test cases as negative ($P = 0.0129$) (Table 3).

Table 3
Investigation of concordance rates between the L-type Wako *Helicobacter pylori* antibody J test and the Enzyme-Linked Immunosorbent Assay.

|                | ELISA Positive | ELISA Negative | Total | $P$-value | $\kappa$ |
|----------------|----------------|----------------|-------|-----------|----------|
| L-HP•J test    | 78             | 12             | 90    | 0.0129    | 0.844    |
| Positive       |                |                |       |           |          |
| L-HP•J test    | 2              | 88             | 90    |           |          |
| Negative       |                |                |       |           |          |
| Total          | 80             | 100            | 180   |           |          |

$P$-values were determined via McNemar’s test.

ELISA, Enzyme-Linked Immunosorbent Assay; L-HP•J, L-type Wako *Helicobacter pylori* antibody J; HP, *Helicobacter pylori*.

**Investigation of cases misdiagnosed by the L-HP•J test**
Cases misdiagnosed by the L-HP•J test included five false negative cases (5.6%) and five false positive cases (5.6%) (Table 4). Among the false positive cases, one subject had a high titre, while the other four subjects had titres slightly above the cut-off value. All false negative subjects had open-type mucosal atrophy.
Table 4
Misdiagnosed cases by the L-type Wako *Helicobacter pylori* antibody J test.

| Case number | Sex | Age  | L-HP•J (U/ml) | Judge-ment | ELISA (U/ml) | Change rate (‰) | Judgment | Kimura-Takemoto classification |
|-------------|-----|------|---------------|------------|--------------|-----------------|---------|--------------------------------|
| False positive cases of L-HP•J |
| 1 | M | 68  | 4.1  | + | 3.3 | - | 0.5 | - | No atrophy |
| 2 | F | 63  | 4.3  | + | 3  | - | 0.6 | - | No atrophy |
| 3 | M | 72  | 5.2  | + | 3  | - | 0.5 | - | No atrophy |
| 4 | F | 54  | 5.2  | + | 5.5 | - | 0.0 | - | No atrophy |
| 5 | M | 73  | 13.6 | + | 4.7 | - | 0.2 | - | No atrophy |
| False negative cases of L-HP•J |
| 6 | F | 63  | 3.9  | - | 14 | + | 3.3 | + | O-3 |
| 7 | F | 76  | 3.1  | - | 15.5 | + | 6 | + | O-3 |
| 8 | F | 69  | 3.5  | - | 4.8 | - | 9.5 | + | O-3 |
| 9 | M | 84  | 2.7  | - | 7.5 | - | 59.2 | + | O-1 |
| 10 | F | 67  | 3.24 | - | 3 | - | 2.7 | + | O-2 |
| False negative cases of ELISA |
| 1 | M | 28  | 16.56 | + | 6.4 | - | 5.7 | + | O-1 |
| 2 | M | 57  | 7.2  | + | 9.7 | - | 13.9 | + | C-2 |
| 3 | F | 69  | 3.5  | - | 4.8 | - | 3.7 | + | O-3 |
| 4 | M | 70  | 5.9  | + | 5.9 | - | 3.9 | + | O-1 |
| 5 | F | 39  | 16.1 | + | 6.9 | - | 5 | + | C-1 |
| 6 | M | 84  | 2.7  | - | 7.5 | - | 59.2 | + | O-1 |
| 7 | F | 67  | 3.24 | - | 3 | - | 2.7 | + | O-2 |
| 8 | M | 56  | 18.2 | + | 3 | - | 6.8 | + | O-1 |
| 9 | M | 66  | 5.5  | + | 5.5 | - | 5.1 | + | O-1 |
| 10 | M | 70  | 18.6 | + | 8.4 | - | 24.1 | + | O-2 |

*H. pylori, Helicobacter pylori, L-HP•J, L-type Wako Helicobacter pylori antibody J.*
Discussion

Invasive diagnostic methods for *H. pylori* infection listed in the Japanese Society for *Helicobacter* Research guidelines [6] include the rapid urease test, microscopic test, and culture test. Non-invasive methods include the UBT, blood *H. pylori* antibody test, and faeces *H. pylori* antigen test. Among them, the blood *H. pylori* antibody test is relatively convenient and widely used. A prevailing method for measuring *H. pylori* antibodies is ELISA.

In this study, we investigated a newly launched kit that can be used with a general-purpose automatic analyser: The L-HP•J test kit. The L-HP•J test can be performed using commercially available automated analysers, such as Hitachi 7180 (Hitachi High-Tech), JCA-BM6050 (JEOL Ltd., Tokyo, Japan), ARCHITECT c16000 (Canon Medical Systems, Tokyo, Japan), and DxC700AU (Beckman Coulter K.K., Tokyo, Japan). The L-HP•J test was launched in April 2016 by FUJIFILM Wako Pure Chemical Corporation and is based on the latex agglutination turbidimetric immunoassay. To our knowledge, this is the first report to evaluate the diagnostic validity of this newly launched kit. We demonstrated that the diagnostic accuracy, sensitivity, and specificity of the L-HP•J test was approximately 95%, and the concordance rate between the L-HP•J test and conventional ELISA was high, with a $\kappa$ statistic of 0.8444. Although ELISA showed high specificity, the 90% CI lower limits for sensitivity of ELISA did not exceed the threshold value of 85%. In addition to this, ELISA had a significant tendency to give false negative results ($P = 0.0129$). From these findings, it can be considered that ELISA tends to underestimate the antibody titre, and that the L-HP•J test is a relatively more accurate kit.

The latex agglutination turbidimetric immunoassay is superior to ELISA in terms of throughput and reducing labour and is expected to greatly contribute to rapid testing. Kita et al. demonstrated that the diagnosis of *H. pylori* infection is improved when two strains from genotypes commonly seen in the Japanese population (#3 and #5) [10] are used. The L-HP•J test we evaluated in this study used the same two antigens as the chemiluminescent test. Our findings show that the accuracy of the L-HP•J test is not inferior to ELISA and that it has a greater sensitivity. Regarding the false positive and false negative cases detected using the L-HP•J test, all but one false positive case had low-positive titres (between 4 U/mL and 8.7 U/mL). It has been reported that approximately 10% of individuals with low-positive titres detected using the L-HP•J test are uninfected [11]. Thus, we believe that this problem arises due to the established cut-off value. Regarding the false negative cases, there were many subjects with open-type mucosal atrophy. This is because, in patients with severe atrophic gastritis, *H. pylori* colonisation is decreased or has spontaneously disappeared, resulting in the decrease of serum antibody [12]. It is important to use additional tests, such as the UBT, to diagnose *H. pylori* infection correctly if the L-HP•J test is not consistent with endoscopic findings, such as in the following two scenarios: (1) when an individual has an open-type mucosal atrophy and endoscopic findings suggest current infection, but the L-HP•J test result is negative; or (2) when endoscopic findings suggest no infection, but the L-HP•J test result has low-positive titres (between 4 U/mL and 8.7 U/mL).

In the present study, we considered both the results of the UBT, which has a high diagnostic accuracy [13], and endoscopic findings based on the Kyoto classification of gastritis. We then diagnosed the presence or
absence of *H. pylori* infection in those subjects whose UBT results and endoscopic findings were consistent. Therefore, subjects who were previously infected with *H. pylori* and those who had type A gastritis could be excluded from the study. Moreover, this was a prospective study and antibody measurements using both kits were performed in-house, which increases the reliability of the study.

There are some limitations of the study. First, it represented a single-centre observational study. To confirm the generality of this kit, a multi-centre study is needed in the future. Second, in some subjects, fresh plasma was used for detection using ELISA and part of the L-HP•J test, while stored serum (harvested within 4 weeks) was also used for some of the L-HP•J tests; therefore, there were differences between subjects in terms of the conditions of the specimens used. However, supplemental data from FUJIFILM Wako Pure Chemical Corporation showed no difference in the titres between fresh plasma and stored serum (harvested within 4 weeks) under conditions of -20 °C. Third, we used the UBT as the gold standard for diagnosing *H pylori* infection; however, its accuracy is not 100% [13]. Fourth, we investigated only non-infected and currently infected cases, not previously infected cases. Therefore, a further study should be conducted to analyse the association between previously infected cases and the antibody titre of the L-HP•J test.

**Conclusions**

The L-HP•J test has a high diagnostic performance and is not inferior to ELISA. It is useful, especially in screening for Helicobacter-pylori infection, due to its high sensitivity. It can be used with various general-purpose automatic analysers because the kit is versatile, easy to use, and convenient. It can, therefore, contribute to the streamlining of clinical laboratory procedures.

**Abbreviations**

Confidence interval (CI); enzyme-linked immunosorbent assay (ELISA); Esophagogastroduodenoscopy (EGD); L-type Wako H. pylori antibody J (L-HP•J); Urea breath test (UBT).

**Declarations**

**Ethics approval and consent to participate**

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent Informed consent to be included in the study, or the equivalent, was obtained from all patients.

**Consent for publication**

Consent for publication has been obtained from patients.

**Availability of data and materials**
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests

**Funding**

This study was funded by FUJIFILM Wako Pure Chemical Corporation. The sponsor had no control over the design, implementation, interpretation of results, writing, or publication of this work.

**Authors' contributions**

H.O and J.F designed the study and wrote the initial draft of the manuscript. Y.T contributed to analysis and interpretation of data and wrote the main manuscript text and prepared figures 1-2 and tables. N.I is a statistician who contributed to analysis and interpretation of the data. K.M is a doctor who conceived the concept of this study (took over this study from FUJIFILM Wako Pure Chemical Corporation), and helped us interview the patients. K.N, S.Y, Y.H, A.I, T.Y, T.H, and T.T have contributed to data collection and interpretation, and critically reviewed the manuscript. All authors approved the final version of the manuscript.

**Acknowledgements**

I would like to thank Dr Satomi Haruki and Dr Mizuki Imai, the medical staff of the Cancer Screening Centre for helping us to interview patients for their history of *H. pylori* eradication and obtain patients’ consent for participating in this study. We received generous support from Kazumi Kaihara, who is a laboratory technician.

**References**

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311–5.

2. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, et al. *Helicobacter pylori* infection and the development of gastric cancer. N Engl J Med 2001;345:784–9.

3. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. In; IARC, Schistosomes, liver flukes and *Helicobacter pylori* Vol. 61. Lyon: IARC; 1994. p. 177–240.

4. Suzuki H, Nishizawa T, Tsugawa H, Hibi T. Molecular approaches and modern clinical strategies for the management of *Helicobacter pylori* infection in Japan. Keio J Med 2012;61:109–19.

5. Nishizawa T, Suzuki H. Mechanisms of *Helicobacter pylori* antibiotic resistance and molecular testing. Front Mol Biosci 2014;1:19.
6. Asaka M, Kato M, Takahashi SI, Fukuda Y, Sugiyama T, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15;1:1–20.

7. Ohara S, Kato M, Saito M, Fukuda S, Kato C, et al. Comparison between a new 13 C-urea breath test, using a film-coated tablet, and the conventional 13 C-urea breath test for the detection of Helicobacter pylori infection. J Gastroenterol 2004;39;7:621–8.

8. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969;1:87–97.

9. Kato M, Inoue K, Murakami K, Kamada T, Haruma K. Kyoto Classification of Gastritis. Tokyo: Nihon Medical Centre 2017:97–110.

10. Kita M, Yokota K, Okada H, Take S, Takenaka R, et al. The genetic diversity of Helicobacter pylori virulence genes is not associated with gastric atrophy progression. Acta Medica Okayama 2013;67;2:93–8.

11. Masayuki I, Susumu O, Yoshikatsu I, Yuko K. Analysis of the gray-zone cutoff values of new serum Helicobacter pylori antibody kits using latex immunoassay. Japanese Journal of Gastroenterology. 2017;114:1968–77. [Article in Japanese]

12. Iino C, Shimoyama T, Oyama T, Chiba D, Umeda T, et al. Evaluation of the appropriate cut-off value for serological diagnosis of Helicobacter pylori infection by comparison with a stool antigen test. Hirosaki Med J 2012;18;63:48–54.

13. Ohara S, Kato M, Asaka M, Toyota T. Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol 1998;33;6–13.